Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $8.25 Consensus Target Price from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given an average rating of “Buy” by the four ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on […]

Related Keywords

Piper Sandler ,News Ratings For Amneal Pharmaceuticals Daily ,Nasdaq ,Amneal Pharmaceuticals Company Profile ,Goldman Sachs Group ,Amneal Pharmaceuticals ,Amneal Pharmaceuticals Inc ,Amneal Pharmaceuticals Stock Down ,Sherbrooke Park Advisers ,Atlanta Consulting Group Advisors ,Hedge Funds Weigh In On Amneal Pharmaceuticals ,Get Free Report ,Marketbeat Ratings ,Truist Financial ,Capital Management ,Park Advisers ,Consulting Group Advisors ,Bayesian Capital Management ,Pharmaceuticals Stock Down ,Get Free ,Amneal Pharmaceuticals Daily ,